Ligand id: 8720

Name: nemolizumab

Compound class Antibody
International Nonproprietary Names
INN number INN
10064 nemolizumab
CIM 331 | CIM331
Nemolizumab is an investigational monoclonal targeting the α subunit of the IL-31 receptor. Nemolizumab has been designed for treating or preventing inflammatory diseases [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide analysis of patented peptide sequences reveals that the heavy and light variable domains of nemolizumab are identical to SEQ ID NO: 210 and SEQ ID NO: 220 respectively, in patent US8575317 B2 [2]. This combination of peptides corresponds to one of the preferred antibodies, designated as H44L17 therein.
Database Links
Specialist databases
IMGT/mAb-DB 538
Other databases
GtoPdb PubChem SID 252827378
Search PubMed clinical trials nemolizumab
Search PubMed titles nemolizumab
Search PubMed titles/abstracts nemolizumab